RESPONSE

The Office has entered a sequence listing requirement in the above-referenced application. Applicants enclose a sequence listing diskette, paper copies of the sequence listing and the required statements.

Amendments to the specification are also being made in regard to the sequence identifiers. The amendments are made solely to conform the specification to the enclosed sequence listing and are fully supported by the original application do not constitute new matter. The amendments to the specification comply with the revisions to 37 C.F.R. § 1.121, and separate exhibits are no longer necessary.

This is a complete response to the referenced Notice. The present application is in compliance with the sequence listings requirements. The response is timely filed in light of the enclosed Request for Extension of Time and appropriate fee. No additional fees are required. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary, Applicants respectfully request a telephone call to the undersigned representative to discuss deduction from Applicants' representatives' Deposit Account No. 50-0786/4050.001200.

Should the Office have any questions, a telephone call to the undersigned Applicants' representative is earnestly solicited.

<div style="text-align: right">

Respectfully submitted,
Williams, Morgan & Amerson, P.C.
Customer No. 23720

Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

</div>

10333 Richmond, Suite 1100
Houston, Texas, 77042
(713) 934-4079

Date: November 17, 2003

SEQUENCE LISTING

<110> SMYTHE, MARK LESLIE
MEUTERMANS, WIM DENIS FRANS
BOURNE, GREGORY THOMAS
MCGEARY, ROSS PETER

<120> SYNTHESIS OF CYCLIC PEPTIDES

<130> 4050.001200

<140> 09/806,036
<141> 2001-07-05

<150> PCT/AU99/00813
<151> 1999-09-24

<150> AU PP 6164
<151> 1998-09-25

<160> 76

<170> PatentIn version 3.2

<210> 1
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = CAT-Arg

<400> 1

Asp Gly Xaa Gly
1

<210> 2
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Gly

```
<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<400>  2

Xaa Xaa Arg Phe
1


<210>  3
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE

<400>  3

Tyr Arg Phe Gly
1


<210>  4
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<400>  4

Xaa Arg Phe Gly
1


<210>  5
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC CYCLIC PEPTIDE


<220>
<221>  MISC_FEATURE
```

```
<222>   (1)..(1)
<223>   Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr


<400>   5

Xaa Arg Phe Gly
1


<210>   6
<211>   4
<212>   PRT
<213>   ARTIFICIAL

<220>
<223>   SYNTHETIC LINEAR PEPTIDE

<400>   6

Gly Gly Gly Gly
1


<210>   7
<211>   4
<212>   PRT
<213>   ARTIFICIAL

<220>
<223>   SYNTHETIC LINEAR PEPTIDE


<220>
<221>   MISC_FEATURE
<222>   (4)..(4)
<223>   Xaa = Sarcosine

<400>   7

Gly Gly Gly Xaa
1


<210>   8
<211>   4
<212>   PRT
<213>   ARTIFICIAL

<220>
<223>   SYNTHETIC LINEAR PEPTIDE


<220>
<221>   MISC_FEATURE
<222>   (3)..(3)
<223>   Xaa = Sarcosine
```

<400> 8

Gly Gly Xaa Gly
1

<210> 9
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = Sarcosine

<400> 9

Gly Xaa Gly Gly
1

<210> 10
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (3)..(4)
<223> Xaa = Sarcosine

<400> 10

Gly Gly Xaa Xaa
1

<210> 11
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>

```
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = Sarcosine

<220>
<221>  MISC_FEATURE

<222>  (4)..(4)
<223>  Xaa = Sarcosine

<400>  11

Gly Xaa Gly Xaa
1


<210>  12
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (2)..(3)
<223>  Xaa = Sarcosine

<400>  12

Gly Xaa Xaa Gly
1


<210>  13
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (2)..(4)
<223>  Xaa = Sarcosine

<400>  13

Gly Xaa Xaa Xaa
1


<210>  14
```

```
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = Asp substituted with OBu

<400>  14

Xaa Val Gly Leu
1


<210>  15
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = Asp substituted with OBu

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = 2-hydroxy-4-methoxybenzyl-Val

<400>  15

Xaa Xaa Gly Leu
1


<210>  16
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = Asp substituted with OBu
```

```
<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa = 2-hydroxy-4-methoxybenzyl-Gly

<400>  16

Xaa Val Xaa Leu
1


<210>  17
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC CYCLIC PEPTIDE

<400>  17

Ala Phe Leu Pro Ala
1               5


<210>  18
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE

<400>  18

Ala Phe Leu Pro Ala
1               5


<210>  19
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = N-(6-nitro-2-hydroxybenzyl)-Phe

<400>  19

Xaa Leu Pro Ala Ala
```

<210> 20
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 20

Phe Leu Pro Ala Ala
1   5

<210> 21
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = NH2CH2CH2SSCH2CH2-Gly

<400> 21

Xaa Arg Pro Phe Gly
1   5

<210> 22
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = HSCH2CH2-Gly

<400> 22

Xaa Arg Phe Gly
1

<210> 23
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = SCH2CH2-Gly

<400> 23

Xaa Arg Pro Phe Gly
1   5

<210> 24
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = HSCH2CH2-Gly

<400> 24

Xaa Arg Pro Phe Gly
1   5

<210> 25
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = Gly substituted with CH2CH2SH

<400> 25

Xaa Arg Pro Phe Gly

<210> 26
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(5-nitro-2-hydroxybenzyl)-Ala

<400> 26

Xaa Phe Leu Pro Ala
1   5

<210> 27
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Ala

<400> 27

Xaa Phe Leu Pro Ala
1   5

<210> 28
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Phe

<400> 28

Xaa Leu Pro Ala Ala
1   5

<210> 29
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 29

Tyr Ala Phe Gly
1

<210> 30
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 30

Phe Leu Pro Ala Ala
1   5

<210> 31
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<400> 31

Xaa Arg Phe Gly
1

<210> 32

<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400> 32

Tyr Xaa Phe Gly
1

<210> 33
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400> 33

Tyr Arg Xaa Gly
1

<210> 34
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

```
<400>  34

Xaa Xaa Phe Gly
1


<210>  35
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400>  35

Xaa Arg Xaa Gly
1


<210>  36
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC CYCLIC PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400>  36

Xaa Xaa Phe Gly
1
```

```
<210>   37
<211>   4
<212>   PRT
<213>   ARTIFICIAL

<220>
<223>   SYNTHETIC CYCLIC PEPTIDE


<220>
<221>   MISC_FEATURE
<222>   (1)..(1)
<223>   Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>
<221>   MISC_FEATURE
<222>   (3)..(3)
<223>   Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400>   37

Xaa Arg Xaa Gly
1


<210>   38
<211>   4
<212>   PRT
<213>   ARTIFICIAL

<220>
<223>   SYNTHETIC LINEAR PEPTIDE


<220>
<221>   MISC_FEATURE
<222>   (1)..(1)
<223>   Xaa = N-(2-hydroxy-6-nitrobenzyl)-Gly

<220>
<221>   MISC_FEATURE
<222>   (2)..(2)
<223>   Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<400>   38

Xaa Xaa Arg Phe
1


<210>   39
<211>   4
<212>   PRT
<213>   ARTIFICIAL

<220>
<223>   SYNTEHTIC LINEAR PEPTIDE
```

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Gly

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400> 39

Xaa Tyr Xaa Phe
1

<210> 40
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTEHTIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Gly

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400> 40

Xaa Tyr Arg Xaa
1

<210> 41
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 41

Gly Tyr Arg Phe
1

```
<210>  42
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC CYCLIC PEPTIDE

<400>  42

Tyr Arg Phe Ala
1


<210>  43
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400>  43

Xaa Arg Xaa Ala
1


<210>  44
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC CYCLIC PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe
```

<400> 44

Xaa Arg Xaa Ala
1

<210> 45
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Ala

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400> 45

Xaa Tyr Xaa Phe
1

<210> 46
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400> 46

Xaa Xaa Phe Gly
1

```
<210>   47
<211>   4
<212>   PRT
<213>   ARTIFICIAL

<220>
<223>   SYNTHETIC CYCLIC PEPTIDE

<400>   47

Tyr Arg Phe Gly
1


<210>   48
<211>   4
<212>   PRT
<213>   ARTIFICIAL

<220>
<223>   SYNTHETIC CYCLIC PEPTIDE

<400>   48

Gly Tyr Arg Phe
1


<210>   49
<211>   4
<212>   PRT
<213>   ARTIFICIAL

<220>
<223>   SYNTHETIC LINEAR PEPTIDE


<220>
<221>   MISC_FEATURE
<222>   (3)..(3)
<223>   Xaa = CAT-Arg

<400>   49

Asp Gly Xaa Gly
1


<210>   50
<211>   4
<212>   PRT
<213>   ARTIFICIAL

<220>
<223>   SYNTHETIC CYCLIC PEPTIDE
```

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = Amb-Arg

<400> 50

Asp Gly Xaa Gly
1

<210> 51
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa = Amb-Gly

<400> 51

Asp Xaa Arg Gly
1

<210> 52
<211> 8
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa = Amb-Arg

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa = Amb-Arg

<400> 52

Asp Gly Xaa Gly Asp Gly Xaa Gly
1   5

<210> 53

```
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = Me-Phe

<400>  53

Ala Xaa Leu Pro Ala
1                 5


<210>  54
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC CYCLIC PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = Phe substituted with Me

<400>  54

Ala Xaa Leu Pro Ala
1                 5


<210>  55
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = a ring contraction auxiliary comprising O or S linked to
       Tyr

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
```

<223> Xaa = Gly linked to an activated or safety catch linker linked to
       resin

<400> 55

Xaa Arg Phe Xaa
1

<210> 56
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = a ring contraction auxiliary comprising O or S linked to
       Arg

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Tyr linked to an activated or safety catch linker linked to
       resin

<400> 56

Xaa Phe Gly Xaa
1

<210> 57
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa = a ring contraction auxiliary comprising O or S linked to
       Phe

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Arg linked to an activated or safety catch linker linked to
       resin

```
<400>  57

Xaa Gly Tyr Xaa
1


<210>  58
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = a ring contraction auxiliary comprising O or S linked to
       Gly

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa = Phe linked to an activated or safety catch linker linked to
       resin

<400>  58

Xaa Tyr Arg Xaa
1


<210>  59
<211>  7
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE

<400>  59

Pro Phe Asn Ser Leu Ala Ile
1               5


<210>  60
<211>  7
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE

<400>  60
```

Asn Ser Leu Ala Ile Pro Phe
1   5

<210>   61
<211>   4
<212>   PRT
<213>   ARTIFICIAL

<220>
<223>   SYNTHETIC CYCLIC PEPTIDE

<400>   61

Phe Phe Phe Phe
1

<210>   62
<211>   5
<212>   PRT
<213>   ARTIFICIAL

<220>
<223>   SYNTHETIC CYCLIC PEPTIDE

<220>
<221>   MISC_FEATURE
<222>   (5)..(5)
<223>   Xaa = Beta-Ala

<400>   62

Phe Trp Lys Gly Xaa
1   5

<210>   63
<211>   7
<212>   PRT

<213>   ARTIFICIAL

<220>
<223>   SYNTHETIC CYCLIC PEPTIDE

<400>   63

Pro Phe Asn Ser Leu Ala Ile
1   5

<210>   64
<211>   14
<212>   PRT

<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 64

Asn Ser Leu Ala Ile Pro Phe Asn Ser Leu Ala Ile Pro Phe
1   5   10

<210> 65
<211> 21
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 65

Asn Ser Leu Ala Ile Pro Phe Asn Ser Leu Ala Ile Pro Phe Asn Ser
1   5   10   15

Leu Ala Ile Pro Phe
            20

<210> 66
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa = Beta-Ala

<400> 66

Leu Asp Val Gly Xaa
1   5

<210> 67 .
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

```
<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa = Beta-Ala

<400>  67

Arg Gly Asp Gly Xaa
1               5


<210>  68
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC CYCLIC PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa = Beta-Ala

<400>  68

Phe Lys Trp Gly Xaa
1               5


<210>  69
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa = substituted Pro

<400>  69

Ala Phe Leu Xaa
1


<210>  70
<211>  4
<212>  PRT
<213>  ARTIFICIAL
```

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 70

Tyr Arg Phe Gly
1

<210> 71
<211> 7
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<400> 71

Tyr Ala Phe Gly Tyr Pro Ser
1   5

<210> 72
<211> 5
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 72

Ala Pro Leu Phe Ala
1   5

<210> 73
<211> 4
<212> PRT
<213> ARTIFICIAL

<220>
<223> SYNTHETIC LINEAR PEPTIDE

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa = Pro-[N-(4-(5-oxyvaleric acid)benzyl)]-L-Alanine allyl ester
       appended to resin

<400> 73

Ala Phe Leu Xaa
1

```
<210>  74
<211>  4
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = N-(2-hydroxy-4-nitrobenzyl)-Ala

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa = Pro-[N-(4-(5-oxyvaleric acid)benzyl)]-L-Alanine allyl ester
       linked to resin

<400>  74

Xaa Phe Leu Xaa
1


<210>  75
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC CYCLIC PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = N-(2-hydroxy-4-nitrobenzyl)-Ala

<400>  75

Xaa Phe Leu Pro Ala
1               5


<210>  76
<211>  5
<212>  PRT
<213>  ARTIFICIAL

<220>
<223>  SYNTHETIC LINEAR PEPTIDE


<220>
```

```
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = a ring contraction auxiliary containing O or S linked to
       Ala

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa = Pro-Backbone linker and resin

<400>  76

Xaa Xaa Leu Xaa Ala
1               5
```